About

Victor Tong, Jr. has served on Aardvark's Board since May 2024. He is a Managing Director at Decheng Capital, where he has worked since the firm's inception in 2012, focusing on biotechnology and medical technology investments in China and the United States. He was previously a Principal at Bay City Capital and a member of the healthcare investment banking division at Morgan Stanley. He has served on the board of CG Oncology, Inc. (Nasdaq: CGON) since July 2023 and on the boards of several private biotechnology companies. Mr. Tong received his B.A. in Molecular and Cell Biology and his B.S. in Business Administration from the University of California, Berkeley. He serves on Aardvark's Nominating and Corporate Governance and Audit Committees.

Roles

Aardvark Therapeutics, Inc.
Director · Current role
May 2024–present
Decheng Capital
Managing Director
2012 - present
Bay City Capital
Principal
Morgan Stanley
Healthcare Investment Banking

External Roles

CG Oncology, Inc. (Nasdaq: CGON)
Director
2023 - present
Baylor Genetics
Director
present
Cellares Corp.
Director
present
Harton Therapeutics
Director
present
Hummingbird Bioscience
Director
present
LevitasBio
Director
present
Take2
Director
present
Watchmaker Genomics
Director
present

Director Compensation

FY 2025
Fees earned or paid in cash
$52,753
ComponentAnnual cash retainers and committee/leadership fees earned in 2025
Option awards
$536,120
ComponentStock options granted during 2025, ASC 718 grant-date fair value
Total
$588,873

Also at Aardvark Therapeutics, Inc.

Related

See how VectorShift works for your firm

Request Demo